JNCP - NHGA Haemonetics Blood Additives__Redacted.pdf

This Justification for Non-Competitive Procurement (JNCP) document details a sole-source procurement by the Defense Health Agency (DHACA), Healthcare Contracting Division for the Naval Hospital Guam Donor Center. The procurement is for Haemonetics 250mL Anticoagulant Citrate Phosphate Double Dextrose (CP2D) and 250mL Additive Solution Formula 3 (AS-3), specialized medical supplies intended for blood and plasma collection using automated apheresis devices. The total estimated value is $23,519.25, with a delivery date of 30 June 2025, and the contract will be firm-fixed-price for Operations and Maintenance funding.

The document justifies the non-competitive procurement through sole/limited source procurement authority, citing that Haemonetics Corporation is the only manufacturer capable of providing these highly specialized medical supplies. Market research conducted in February 2025 confirmed no other distributors exist that can meet the government's requirements. The Naval Hospital Guam-Agana and DHACA will continue to survey the market for potential alternative vendors in future procurements, but currently, Haemonetics is determined to be the sole source capable of supplying these specific blood collection and processing solutions.